GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (XTER:DMP) » Definitions » Earnings per Share (Diluted)

Dermapharm Holding SE (XTER:DMP) Earnings per Share (Diluted) : €1.92 (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Earnings per Share (Diluted)?

Dermapharm Holding SE's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was €0.62. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €1.92.

Dermapharm Holding SE's EPS (Basic) for the three months ended in Mar. 2025 was €0.62. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was €1.92.

Dermapharm Holding SE's EPS without NRI for the three months ended in Mar. 2025 was €0.62. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was €1.92.

During the past 12 months, Dermapharm Holding SE's average EPS without NRIGrowth Rate was 82.90% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -17.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.30% per year.

During the past 12 years, Dermapharm Holding SE's highest 3-Year average EPS without NRI Growth Rate was 38.90% per year. The lowest was -17.70% per year. And the median was 6.15% per year.


Dermapharm Holding SE Earnings per Share (Diluted) Historical Data

The historical data trend for Dermapharm Holding SE's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Earnings per Share (Diluted) Chart

Dermapharm Holding SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 3.89 2.49 1.16 2.11

Dermapharm Holding SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.32 0.60 0.38 0.62

Competitive Comparison of Dermapharm Holding SE's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's PE Ratio distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's PE Ratio falls into.


;
;

Dermapharm Holding SE Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Dermapharm Holding SE's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(113.787-0)/53.840
=2.11

Dermapharm Holding SE's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2025 is calculated as

Diluted Earnings Per Share (Q: Mar. 2025 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(33.405-0)/53.879
=0.62

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Dermapharm Holding SE  (XTER:DMP) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Dermapharm Holding SE Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
Executives
Wilhelm Beier Supervisory Board
Dr. Hans-georg Feldmeier Board of Directors
Christof Dreibholz Board of Directors
Lothar Lanz Supervisory Board
Anja Schorn Board Member Themis Beteiligungs-AG
Hilde Neumeyer Board of Directors

Dermapharm Holding SE Headlines

No Headlines